{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:24:46Z","timestamp":1779906286197,"version":"3.53.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104244"],"award-info":[{"award-number":["82104244"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-67627-0","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T17:01:40Z","timestamp":1722013300000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Unveiling the adverse events of Nusinersen in spinal muscular atrophy management based on FAERS database"],"prefix":"10.1038","volume":"14","author":[{"given":"Ying","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"issue":"1","key":"67627_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri, E. et al. Spinal muscular atrophy. Nat. Rev. Dis. Primers 8(1), 52 (2022).","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"4","key":"67627_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.tins.2020.11.009","volume":"44","author":"B Wirth","year":"2021","unstructured":"Wirth, B. Spinal muscular atrophy: In the challenge lies a solution. Trends Neurosci. 44(4), 306\u2013322 (2021).","journal-title":"Trends Neurosci."},{"issue":"1","key":"67627_CR3","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41431-020-00714-8","volume":"29","author":"S Zhao","year":"2021","unstructured":"Zhao, S. et al. NGS-based spinal muscular atrophy carrier screening of 10,585 diverse couples in China: A pan-ethnic study. Eur. J. Hum. Genet. 29(1), 194\u2013204 (2021).","journal-title":"Eur. J. Hum. Genet."},{"issue":"1","key":"67627_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/dmcn.14027","volume":"61","author":"T Gidaro","year":"2019","unstructured":"Gidaro, T. & Servais, L. Nusinersen treatment of spinal muscular atrophy: Current knowledge and existing gaps. Dev. Med. Child Neurol. 61(1), 19\u201324 (2019).","journal-title":"Dev. Med. Child Neurol."},{"key":"67627_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy, S. M. Nusinersen: First global approval. Drugs 77, 473\u2013479 (2017).","journal-title":"Drugs"},{"key":"67627_CR6","first-page":"S210","volume":"27","author":"E Mercuri","year":"2017","unstructured":"Mercuri, E. et al. Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): End of study results from the phase 3 CHERISH study. Neuromusc. Disord. 27, S210 (2017).","journal-title":"Neuromusc. Disord."},{"issue":"10","key":"67627_CR7","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga, C. A. et al. Results from a phase 1 study of Nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy. Neurology 86(10), 890\u2013897 (2016).","journal-title":"Neurology"},{"issue":"7","key":"67627_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri, E. et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N. Engl. J. Med. 378(7), 625\u2013635 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"67627_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12883-023-03063-3","volume":"23","author":"H Yang","year":"2023","unstructured":"Yang, H. et al. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with Nusinersen after loading period in Western China: A retrospective study. BMC Neurol. 23(1), 35 (2023).","journal-title":"BMC Neurol."},{"key":"67627_CR10","doi-asserted-by":"publisher","first-page":"1152318","DOI":"10.3389\/fped.2023.1152318","volume":"11","author":"ZJ Zhong","year":"2023","unstructured":"Zhong, Z. J. et al. Adverse events in the treatment of spinal muscular atrophy in children and adolescents with Nusinersen: A systematic review and meta-analysis. Front. Pediatr. 11, 1152318 (2023).","journal-title":"Front. Pediatr."},{"key":"67627_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jad.2023.11.076","volume":"347","author":"H Zhu","year":"2024","unstructured":"Zhu, H. et al. Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database. J. Affect. Disord. 347, 45\u201350 (2024).","journal-title":"J. Affect. Disord."},{"key":"67627_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2023.103828","volume":"90","author":"Q Zhou","year":"2023","unstructured":"Zhou, Q. et al. Adverse events of epidiolex: A real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database. Asian J. Psychiatry 90, 103828 (2023).","journal-title":"Asian J. Psychiatry"},{"key":"67627_CR13","first-page":"1","volume":"5","author":"Y Jiang","year":"2023","unstructured":"Jiang, Y. et al. The correlation of Esketamine with specific adverse events: A deep dive into the FAERS database. Eur. Arch. Psychiatry Clin. Neurosci. 5, 1\u20139 (2023).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"67627_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","volume":"346","author":"Y Jiang","year":"2024","unstructured":"Jiang, Y. et al. Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database. J. Affect. Disord. 346, 223\u2013229 (2024).","journal-title":"J. Affect. Disord."},{"issue":"8","key":"67627_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","volume":"27","author":"EG Brown","year":"2004","unstructured":"Brown, E. G. Using MedDRA: Implications for risk management. Drug Saf. 27(8), 591\u2013602 (2004).","journal-title":"Drug Saf."},{"issue":"8","key":"67627_CR16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol. Drug Saf. 13(8), 519\u2013523 (2004).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"6","key":"67627_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans, S. J. W., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10(6), 483\u2013486 (2001).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"67627_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A. et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54, 315\u2013321 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"67627_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"W DuMouchel","year":"1999","unstructured":"DuMouchel, W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am. Stat. 53(3), 177\u2013190 (1999).","journal-title":"Am. Stat."},{"issue":"11","key":"67627_CR20","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"C Darryl","year":"2019","unstructured":"Darryl, C. et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the phase 2 NURTURE study. Neuromusc. Disord. 29(11), 842\u2013856 (2019).","journal-title":"Neuromusc. Disord."},{"key":"67627_CR21","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1016\/j.nmd.2020.08.265","volume":"30","author":"R Finkel","year":"2020","unstructured":"Finkel, R. et al. SMA-THERAPY: P. 266 Nusinersen in infantile-onset spinal muscular atrophy: results from longer-term treatment from the open-label SHINE extension study. Neuromusc. Disord. 30, S124 (2020).","journal-title":"Neuromusc. Disord."},{"key":"67627_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","volume":"39","author":"J Erdos","year":"2022","unstructured":"Erdos, J. & Wild, C. Mid-and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with Nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data. Eur. J. Paediatr. Neurol. 39, 1\u201310 (2022).","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"11","key":"67627_CR23","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","volume":"91","author":"L Maggi","year":"2020","unstructured":"Maggi, L. et al. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J. Neurol. Neurosurg. Psychiatry 91(11), 1166\u20131174 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"67627_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-020-01763-8","volume":"20","author":"J Seemiller","year":"2020","unstructured":"Seemiller, J. et al. Intrathecal blood injection: A case report of a rare complication of an epidural blood patch. BMC Neurol. 20, 1\u20135 (2020).","journal-title":"BMC Neurol."},{"issue":"1","key":"67627_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13256-023-03754-y","volume":"17","author":"A Ferrieri","year":"2023","unstructured":"Ferrieri, A. et al. Inadvertent intrathecal drug injection while treating low back pain: A case report and review of the literature. J. Med. Case Rep. 17(1), 76 (2023).","journal-title":"J. Med. Case Rep."},{"issue":"2","key":"67627_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bjae.2019.11.002","volume":"20","author":"EM Delhaas","year":"2020","unstructured":"Delhaas, E. M. & Huygen, F. Complications associated with intrathecal drug delivery systems. BJA Educ. 20(2), 51\u201357 (2020).","journal-title":"BJA Educ."},{"issue":"21","key":"67627_CR27","doi-asserted-by":"publisher","first-page":"e2103","DOI":"10.1212\/WNL.0000000000207878","volume":"101","author":"V Aponte Ribero","year":"2023","unstructured":"Aponte Ribero, V. et al. Systematic literature review of the natural history of spinal muscular atrophy: Motor function, scoliosis, and contractures. Neurology 101(21), e2103\u2013e2113 (2023).","journal-title":"Neurology"},{"key":"67627_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.604197","volume":"15","author":"V Belov","year":"2021","unstructured":"Belov, V. et al. Large-volume intrathecal administrations: Impact on CSF pressure and safety implications. Front. Neurosci. 15, 604197 (2021).","journal-title":"Front. Neurosci."},{"issue":"5","key":"67627_CR29","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1093\/neuros\/nyaa053","volume":"87","author":"AK Hell","year":"2020","unstructured":"Hell, A. K. et al. Children with spinal muscular atrophy with prior growth-friendly spinal implants have better results after definite spinal fusion in comparison to untreated patients. Neurosurgery 87(5), 910\u2013917 (2020).","journal-title":"Neurosurgery"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67627-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67627-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67627-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T17:02:30Z","timestamp":1722013350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67627-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["67627"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-67627-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,25]]},"assertion":[{"value":"5 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17138"}}